Addex: Surges as partner Janssen gets FDA nod for epilepsy treatment study
21/01/2021 10:54
** U.S.-listed shares of Switzerland-based pharma co
ADXN.O more than double to $23.70 premarket, set to open at
1-mth high
** Stock is top pct gainer across U.S. exchanges premarket
** ADXN says partner Janssen Pharmaceuticals, a unit of
Johnson & Johnson JNJ.N , received U.S. FDA approval to start a
mid-stage, proof-of-concept study of ADX71149, ADXN's
experimental treatment for epilepsy urn:newsml:reuters.com:*:nGNX2Svz7Y
** Says first patient in study expected to be treated in Q2
2021; study to test efficacy of ADX71149 in combination with
another epilepsy treatment
** ADX71149 being developed as a treatment for epilepsy,
anxiety, schizophrenia and other undisclosed indications
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))